13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001615982
Total reported value
$3.3B
$3.3B
27 檔
33.9%
According to the latest 13F quarterly dataset, Venrock Adviser, LLC managed an equity portfolio of $3.3B at the end of Q4 2025, spanning 27 distinct U.S. exchange-listed positions.
In Q4 2025, Venrock Adviser, LLC adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 31.67% | +7.50% | — | |
| 2 | ORKA | Oruka Therapeutics Inc | Stock-Other | 6.21% | +4.37% | — | |
| 3 | VRDN | Viridian Therapeutics Inc | Stock-Other | 5.97% | -1.02% | — | |
| 4 | SYRE | Spyre Therapeutics Inc | Stock-Other | 5.96% | +1.10% | +37.24% | |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 5.37% | -4.86% | EXIT | |
| 6 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.39% | -0.19% | -44.42% | |
| 7 | SVRA | Savara Inc | Stock-Other | 4.09% | -0.05% | +8.35% | |
| 8 | COGT | Cogent Biosciences Inc | Stock-Other | 3.51% | -0.94% | -50.00% | |
| 9 | ERAS | Erasca Inc | Stock-Other | 3.28% | +0.05% | — | |
| 10 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 3.27% | -1.18% | — | |
| 11 | MAZE | Maze Therapeutics Inc | Stock-Other | 3.17% | -0.33% | +25.82% | |
| 12 | JBIO | Jade Biosciences Inc | Stock-Other | 2.45% | +0.48% | — | |
| 13 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.45% | -1.72% | — | |
| 14 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.29% | -0.62% | -13.96% | |
| 15 | ✓ | Engene Holdings Inc | Stock-Other | 2.13% | -1.21% | EXIT | |
| 16 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.10% | -0.01% | — | |
| 17 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.04% | -0.21% | +4.08% | |
| 18 | UPB | Upstream Bio Inc | Stock-Other | 1.57% | — | — | |
| 19 | HELP | Cybin Inc | Stock-Other | 1.55% | +0.08% | — | |
| 20 | ✓ | Zura Bio LTD | Stock-Other | 1.38% | -0.28% | +15.41% | |
| 21 | VOR | Vor Biopharma Inc | Stock-Other | 1.26% | -0.33% | +288.78% | |
| 22 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.25% | -0.30% | +53.73% | |
| 23 | SEPN | Septerna Inc | Stock-Other | 0.84% | -0.45% | EXIT | |
| 24 | SRZN | Surrozen Inc | Stock-Other | 0.71% | -0.19% | — | |
| 25 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.71% | +0.03% | — | |
| 26 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.34% | +0.21% | — | |
| 27 | ✓ | Casi Pharmaceuticals Inc | Stock-Other | 0.04% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | +12.7% | — | Unchanged |
| 2 | SYRE | Spyre Therapeutics Inc | +3.4% | +37.24% | Add |
| 3 | ORKA | Oruka Therapeutics Inc | +1.7% | — | Unchanged |
| 4 | SVRA | Savara Inc | +1.5% | +8.35% | Add |
| 5 | MAZE | Maze Therapeutics Inc | +1.4% | +25.82% | Add |
| 6 | VRDN | Viridian Therapeutics Inc | +1.3% | — | Unchanged |
| 7 | ERAS | Erasca Inc | +1.1% | — | Unchanged |
| 8 | JBIO | Jade Biosciences Inc | +0.9% | — | Unchanged |
| 9 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.8% | — | Unchanged |
| 10 | DYN | Dyne Therapeutics Inc | +0.6% | — | Unchanged |
| 11 | CTMX | Cytomx Therapeutics Inc | +0.5% | — | Unchanged |
| 12 | UPB | Upstream Bio Inc | +0.3% | — | Unchanged |
| 13 | ✓ | Crescent Biopharma Inc. | +0.3% | +53.73% | Add |
| 14 | COGT | Cogent Biosciences Inc | +0.3% | -50.00% | Trim |
| 15 | ✓ | Zura Bio LTD | +0.3% | +15.41% | Add |
| 16 | SRZN | Surrozen Inc | +0.3% | — | Unchanged |
| 17 | CGEM | Cullinan Therapeutics Inc | +0.3% | — | Unchanged |
| 18 | ✓ | Engene Holdings Inc | +0.2% | -5.45% | Trim |
| 19 | SEPN | Septerna Inc | +0.2% | — | Unchanged |
| 20 | ARTV | Artiva Biotherapeutics Inc | +0.1% | — | Unchanged |
| 21 | ✓ | Casi Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 22 | DNTH | Dianthus Therapeutics Inc | -0.1% | +4.08% | Add |
| 23 | VOR | Vor Biopharma Inc | -0.1% | +288.78% | Add |
| 24 | ELVN | Enliven Therapeutics Inc | -1.3% | — | Unchanged |
| 25 | ORIC | Oric Pharmaceuticals Inc | -2.2% | -13.96% | Trim |
| 26 | OCUL | Ocular Therapeutix Inc | -4.3% | -44.42% | Trim |
| 27 | ✓ | — | EXIT | Sold out | |
| 28 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 29 | ABVX | Abivax Sa-adr | — | EXIT | Sold out |
| 30 | HELP | Cybin Inc | — | NEW | New buy |
| 31 | CATBUSD | Astria Therapeutics Inc | — | EXIT | Sold out |
| 32 | PHVS | Pharvaris N.V. | — | EXIT | Sold out |
| 33 | ✓ | — | EXIT | Sold out | |
| 34 | TENX | Tenax Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Venrock Adviser, LLC reported a total U.S. public equity portfolio value of $3.3B across 27 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APGE, ORKA, VRDN) accounted for 33.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
HELP
市值: $31.4M
Top Position Liquidated / Trimmed
前期市值: $196.3M
During Q4 2025, Venrock Adviser, LLC's top holdings by market value included APGE (31.7%)、ORKA (6.2%)、VRDN (6.0%). The largest single position, APGE, represented 31.7% of total portfolio value.
In Q4 2025, Venrock Adviser, LLC made 19 total portfolio adjustments, initiating 1 new buys, adding to 7 positions, trimming 4 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.